HRMY
HealthcareHarmony Biosciences Holdings, Inc. · Biotechnology · $2B
What is Harmony Biosciences Holdings, Inc.?
Harmony Biosciences Holdings is a commercial-stage pharmaceutical company focused on rare neurological disorders. Based in Plymouth Meeting, Pennsylvania, the company has built its commercial foundation around a single approved therapy targeting narcolepsy.
Harmony Biosciences develops and commercializes therapies for patients living with rare neurological conditions in the United States. The company generates revenue through the sale of WAKIX, an FDA-approved medication indicated for excessive daytime sleepiness in adult patients with narcolepsy. As a commercial-stage company, its business model centers on driving adoption of WAKIX among sleep specialists and neurologists while exploring opportunities to expand its pipeline and patient reach.
Harmony Biosciences Holdings was incorporated in 2017 and adopted its current name in February 2020, with headquarters in Plymouth Meeting, Pennsylvania.
- WAKIX — approved treatment for excessive daytime sleepiness in narcolepsy
- Rare neurological disorder drug development
- Specialty pharmaceutical commercialization in the US market
Is HRMY a Good Stock to Buy?
UQS Score rates HRMY as Very Good overall.
Harmony Biosciences stands out on the Quality and Risk pillars, reflecting a business profile that appears financially disciplined relative to its small-cap pharma peers. The Growth pillar also registers as Good, suggesting the company's commercial trajectory remains constructive. Valuation is rated Attractive, which may interest investors seeking exposure to specialty pharma without paying a premium multiple.
The Moat pillar comes in at Neutral, a reminder that single-product pharmaceutical companies face inherent concentration risk and competitive pressure over time.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does HRMY pay dividends?
No — Harmony Biosciences Holdings, Inc. does not currently pay a dividend.
HRMY does not currently pay a dividend. For a commercial-stage specialty pharma company, this is typical — capital is generally directed toward supporting the commercial launch of WAKIX, funding pipeline development, and strengthening the balance sheet rather than returning cash to shareholders through distributions.
When does HRMY report earnings?
Harmony Biosciences reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Each quarterly report provides an update on WAKIX prescription trends, revenue trajectory, and operating expense management — the key metrics investors in single-product pharma companies tend to watch most closely. Results have reflected the company's ongoing effort to grow its commercial footprint within the narcolepsy market.
For the most recent quarter's results and guidance commentary, visit Harmony Biosciences' investor relations page directly.
What if I invested in Harmony Biosciences Holdings, Inc.?
Based on Harmony Biosciences Holdings, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
HRMY Long-term Outlook
Harmony Biosciences' Good Growth profile and Strong Risk rating together suggest a company that is expanding its commercial reach while managing downside exposure with relative discipline. The Attractive Valuation label indicates the market may not yet be fully pricing in the company's growth potential. That said, single-asset pharmaceutical businesses carry binary risk tied to their lead product's continued market performance and any pipeline outcomes.
Growth drivers
- Continued WAKIX adoption among narcolepsy patients and prescribing specialists
- Potential pipeline expansion into adjacent rare neurological indications
- Underpenetrated narcolepsy market with room for patient identification growth
Key risks
- Single-product revenue concentration creates vulnerability to competitive or regulatory disruption
- Neutral Moat rating signals limited structural protection against future entrants
- Small-cap pharma companies face elevated financing and execution risk versus larger peers
HRMY vs Peers
Harmony Biosciences operates in a competitive rare-disease and specialty pharma landscape alongside companies pursuing different therapeutic strategies.
Vir focuses on infectious disease and immunology rather than neurology, representing a distinct therapeutic and commercial model.
Nektar pursues a broad pipeline approach across immunology and oncology, contrasting with Harmony's focused rare neurological positioning.
Nuvation Bio concentrates on oncology drug development, operating at an earlier clinical stage than Harmony's commercial-stage model.
Frequently Asked Questions
What does Harmony Biosciences do?
Harmony Biosciences is a commercial-stage pharmaceutical company that develops and sells therapies for rare neurological disorders in the United States. Its primary marketed product, WAKIX, is approved to treat excessive daytime sleepiness in adult patients with narcolepsy. The company focuses on specialty neurology and works to grow awareness and access for underserved patient populations.
Does HRMY pay dividends?
HRMY does not currently pay a dividend. As a commercial-stage specialty pharma company, Harmony Biosciences prioritizes reinvesting capital into its commercial operations and potential pipeline development rather than distributing cash to shareholders.
When does HRMY report earnings?
Harmony Biosciences reports on a quarterly cadence, as is standard for US-listed companies. Specific dates are not covered by our data source — check the company's investor relations page for the most current earnings schedule and recent results.
Is HRMY a good stock to buy?
UQS Score rates HRMY as Very Good, with Strong marks on Quality and Risk and a Good Growth profile. The Valuation pillar is rated Attractive. However, the Neutral Moat rating reflects the concentration risk inherent in a single-product pharmaceutical business. The complete pillar breakdown is available to Pro members.
Is HRMY overvalued?
The UQS Valuation pillar for HRMY is rated Attractive, suggesting the stock may be reasonably priced relative to its fundamentals and sector peers. Valuation assessments can shift with earnings results and market conditions, so reviewing the full metrics through a Pro account provides the most current picture.
How does HRMY compare to its competitors?
Harmony Biosciences occupies a distinct niche in rare neurological disorders with a commercial-stage product, while peers like Vir Biotechnology, Nektar Therapeutics, and Nuvation Bio operate across infectious disease, immunology, and oncology. HRMY's commercial revenue base differentiates it from earlier-stage competitors in the small-cap biotech space.
What is HRMY's market cap bracket?
HRMY is classified as a small-cap stock. This places it in a segment of the market that can offer meaningful growth potential but typically carries higher volatility and liquidity risk compared to mid-cap or large-cap pharmaceutical companies.
Who founded Harmony Biosciences?
Harmony Biosciences was incorporated in 2017 and adopted its current name in February 2020. Detailed founding history, including key executives involved in the company's formation, is publicly available through the company's official disclosures and investor relations materials.
Is HRMY a long-term quality investment?
From a long-term quality standpoint, HRMY's Strong Quality and Risk pillar ratings indicate a financially disciplined operation relative to small-cap pharma peers. The key long-term consideration is whether the company can diversify beyond its single approved product — the Neutral Moat rating reflects this structural question. Pro members can view the full analysis.
What is the main competitive advantage of Harmony Biosciences?
Harmony Biosciences holds an approved, commercialized product in a rare and underserved neurological condition — narcolepsy — where patient diagnosis rates remain low. This gives the company an established revenue base and specialist relationships. However, the UQS Moat pillar rates this advantage as Neutral, reflecting the competitive dynamics of the specialty pharma market.
What sector does HRMY belong to?
HRMY belongs to the Healthcare sector, specifically within specialty and rare-disease pharmaceuticals. Investors interested in this segment can explore other [healthcare sector stocks](/sector/healthcare) rated by UQS Score for broader context.
Is HRMY a growth stock or value stock?
HRMY shows characteristics of both. The Growth pillar is rated Good, reflecting a positive commercial trajectory for WAKIX, while the Valuation pillar is rated Attractive — suggesting the stock is not priced at a significant premium. This combination may appeal to investors seeking growth exposure without elevated valuation risk.
Unlock Full HRMY Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access complete financial metrics and trend data
- ✓Compare HRMY against sector peers side by side
- ✓See the full Quality and Risk pillar breakdown
- ✓Track Valuation changes as new earnings are reported
- ✓Get the complete analyst-grade view in one place
Pro Analysis
HRMY — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 70.0 | 78.3 | 43.0 | 79.2 | 98.1 | 99.0 | 0.0 |
| May 21, 2026 | 70.0 | 78.3 | 43.0 | 79.2 | 98.1 | 98.6 | 0.0 |
| May 14, 2026 | 70.0 | 78.3 | 43.0 | 79.2 | 98.1 | 98.7 | 0.0 |
| May 12, 2026 | 70.0 | 78.3 | 43.0 | 79.2 | 98.1 | 98.4 | 0.0 |
| Apr 22, 2026 | 70.0 | 84.4 | 43.0 | 79.2 | 99.0 | 100.0 | -7.5 |
| Apr 2, 2026 | 77.5 | 84.4 | 43.0 | 79.2 | 99.0 | 100.0 | — |
HRMY — Pillar Breakdown
Quality
— 78.3/100 (25%)Harmony Biosciences Holdings, Inc. demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 79.2/100 (20%)Harmony Biosciences Holdings, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 98.1/100 (15%)Harmony Biosciences Holdings, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 98.9/100 (15%)Harmony Biosciences Holdings, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 43/100 (25%)Harmony Biosciences Holdings, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for HRMY.
Score Composition
Financial Data
More Stock Analysis
How is the HRMY UQS Score Calculated?
The UQS (Unified Quality Score) for Harmony Biosciences Holdings, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Harmony Biosciences Holdings, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Harmony Biosciences Holdings, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.